Abstract
Dengue human infection models present an opportunity to explore a vaccine, antiviral, or immuno-compound’s potential for clinical benefit in a controlled setting. Herein, we report the outcome of a phase 1, open-label assessment of a DENV-3 challenge model. In this study, 9 participants received a subcutaneous inoculation with 0.5ml of a 1.4×103 PFU/ml suspension of the DENV-3 strain CH53489. All subjects developed RNAemia within 7 days of inoculation, with peak titers ranging from 3.13×104 to 7.02×108 GE/ml. Symptoms and clinical lab abnormalities consistent with mild dengue infection were observed in all subjects. DENV-3 specific seroconversion was observed by 14 days after inoculation, along with DENV-3 specific memory T cell responses. RNAseq and serum cytokine analysis revealed the presence of an antiviral transcriptional and cytokine response to infection that overlapped with the period of viremia. The magnitude and frequency of clinical and immunologic endpoints correlated with an individual’s peak viral titer.
Competing Interest Statement
SJ Thomas is an academic and executes clinical trials and other research related to dengue. The funding for these is provided by federal and sponsored funding. These relationships are between his University and the funder. He currently has funding related to dengue from Janssen, Merck, Atea, NIH, and CDMRP. He also sits on advisory boards and review committees related to dengue countermeasure development. In some cases, he is compensated for his time and effort with monies, equity, or both. Current personal relationships of this variety include Merck (chair, scientific ad committee, dengue vaccines, financial comp.), PrimeVax (member, scientific ad board, dengue use in immuno-oncology, equity), Island Pharma (member, scientific ad board, dengue drug, equity), and Takeda (member, advisory board, dengue vaccines, financial comp; chair, dengue case adjudication committee, dengue vaccine, financial comp). He also participates in similar advisory and committee positions for non-dengue related countermeasure development work. He states that none of the work above relates to the submitted manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Clinical Trial
NCT04298138
Funding Statement
Funding for this research was provided by the Department of Defense, Medical Research and Material Command, the Military Infectious Disease Research Program, and the State of New York.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the Dengue Human Infection Model and associated analysis was approved by the State University of New York Upstate Medical University (SUNY-UMU) and the Department of Defense's Human Research Protection Office
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors declare that all data supporting the findings of this study are available within this article and its Supplementary Information files, or from the corresponding author upon reasonable request. RNAseq gene expression data have been deposited in the NCBI Gene Expression Omnibus (GEO GSE216328).
